olivLaw · US equity research
Medpace Holdings, Inc. MEDP
Services-Commercial Physical & Biological Research · SIC 8731 · Vertical: Services-Commercial Physical & Biological Research (SIC 8731)
Medpace is a contract research organization (CRO) that runs full-service clinical trials for small and mid-sized biotech and pharma companies. In Q3 2026 net new awards exceeded revenue, management narrowed its revenue guidance range and approved a new buyback program.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Medpace Holdings, Inc. (MEDP) stock was 656.77 USD (−1.01% on the day), with market capitalisation 18.4 bn USD, P/E 36.4 on diluted EPS of 18.03 USD over the last 12 months, beta 0.98, 52-week range 393.42–692.68 USD. Latest reported quarter (Q3 2026): revenue of 716.0 m USD (+8.5% YoY), net income of 137.5 m USD (+23.7% YoY), diluted EPS 4.84 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 55.2
- strong (55–70)
- Bollinger (20, 2)
- 590.36 – 697.38
- in the upper half of the band · %B 0.62 · band width 16.6%
- SMA 50 / 200
- 621.39 / 530.06
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 13.81 / 14.25
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +5.8% | −1.1% | +6.9 pp | — |
| 3 months | +11.7% | −0.5% | +12.2 pp | — |
| 6 months | +53.9% | +4.4% | +49.5 pp | — |
| Year to date | +16.9% | +12.3% | +4.6 pp | — |
| 1 year | +10.5% | +13.5% | −3.1 pp | +14.7% |
| 3 years | +139.5% | +76.4% | +63.1 pp | −23.9% |
| 5 years | +190.8% | +63.7% | +127.1 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 536.6 m | 558.6 m | 603.3 m | 659.9 m | 708.5 m | 706.6 m | 707.3 m | 716.0 m |
| SG&A | 45.4 m | 57.9 m | 46.7 m | 48.1 m | 44.9 m | 47.9 m | 48.1 m | 51.8 m |
| Operating income | 125.4 m | 113.5 m | 126.3 m | 141.8 m | 153.3 m | 141.5 m | 146.8 m | 165.5 m |
| Pre-tax income | 133.9 m | 118.2 m | 124.5 m | 142.8 m | 156.8 m | 147.6 m | 151.7 m | 170.9 m |
| Income tax | 16.9 m | 3.6 m | 34.3 m | 31.7 m | 21.7 m | 23.7 m | 30.3 m | 33.4 m |
| Net income | 117.0 m | 114.6 m | 90.3 m | 111.1 m | 135.1 m | 123.9 m | 121.4 m | 137.5 m |
| Diluted EPS | 3.67 ≈ | 3.67 | 3.10 | 3.86 | 4.66 ≈ | 4.28 | 4.25 | 4.84 |
| Operating cash flow | 190.7 m | 125.8 m | 148.5 m ≈ | 246.2 m ≈ | 192.7 m | 151.8 m | 162.0 m ≈ | 216.6 m ≈ |
| Capex | 7.6 m | 10.0 m | 6.1 m ≈ | 10.7 m ≈ | 4.5 m | 6.8 m | 23.9 m ≈ | 20.2 m ≈ |
| Share repurchases | 169.9 m | 371.9 m | 540.9 m ≈ | 4.6 m ≈ | 0 | 0 | 294.8 m ≈ | 0 ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 68 percentile of its own 41-quarter history (min 23.3, median 33.1, max 248.8; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 704.6 m | 861.0 m | 925.9 m | 1.1 bn | 1.5 bn | 1.9 bn | 2.1 bn | 2.5 bn |
| Revenue YoY | +61.5% | +22.2% | +7.5% | +23.4% | +27.8% | +29.2% | +11.8% | +20.0% |
| Net income | 73.2 m | 100.4 m | 145.4 m | 181.8 m | 245.4 m | 282.8 m | 404.4 m | 451.1 m |
| Net income YoY | +87.1% | +37.2% | +44.7% | +25.1% | +34.9% | +15.3% | +43.0% | +11.6% |
| Diluted EPS | 1.97 | 2.67 | 3.84 | 4.81 | 7.28 | 8.88 | 12.63 | 15.28 |
| Diluted EPS YoY | +101.0% | +35.5% | +43.8% | +25.3% | +51.4% | +22.0% | +42.2% | +21.0% |
| net % | 10.4% | 11.7% | 15.7% | 15.9% | 16.8% | 15.0% | 19.2% | 17.8% |
| Free cash flow | 140.6 m | 184.0 m | 227.3 m | 235.1 m | 351.2 m | 396.7 m | 572.3 m | 681.9 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 497.0 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 459.1 m USD
- Total assets
- 2.0 bn USD
- Debt / equity
- unavailable
- Current ratio
- 0.74x
- ROE
- 70.2%
- ROA
- 22.1%
- FCF margin
- 26.9%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 925.9 m | 1.1 bn | 1.5 bn | 1.9 bn | 2.1 bn | 2.5 bn | SEC (XBRL)· 10 Feb 2026verified |
| SG&A | 92.2 m | 108.4 m | 131.4 m | 161.4 m | 180.2 m | 197.6 m | SEC (XBRL)· 10 Feb 2026verified |
| Operating income | 167.0 m | 198.6 m | 278.7 m | 336.8 m | 446.9 m | 534.9 m | SEC (XBRL)· 10 Feb 2026verified |
| Pre-tax income | 168.5 m | 201.9 m | 282.9 m | 335.7 m | 475.9 m | 542.4 m | SEC (XBRL)· 10 Feb 2026verified |
| Income tax | 23.1 m | 20.0 m | 37.5 m | 52.9 m | 71.5 m | 91.3 m | SEC (XBRL)· 10 Feb 2026verified |
| Net income | 145.4 m | 181.8 m | 245.4 m | 282.8 m | 404.4 m | 451.1 m | SEC (XBRL)· 10 Feb 2026verified |
| Diluted EPS | 3.84 | 4.81 | 7.28 | 8.88 | 12.63 | 15.28 | SEC (XBRL)· 10 Feb 2026verified |
| Weighted average diluted shares | 37.7 m | 37.7 m | 33.7 m | 31.8 m | 32.0 m | 29.5 m | SEC (XBRL)· 10 Feb 2026verified |
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 277.8 m | 461.3 m | 28.3 m | 245.4 m | 669.4 m | 497.0 m | SEC (XBRL)· 10 Feb 2026verified |
| Current assets | 473.7 m | 690.9 m | 334.0 m | 593.8 m | 1.0 bn | 989.6 m | SEC (XBRL)· 10 Feb 2026verified |
| Property, plant & equipment, net | 85.0 m | 93.2 m | 109.8 m | 120.6 m | 123.6 m | 131.1 m | SEC (XBRL)· 10 Feb 2026verified |
| Goodwill | 662.4 m | 662.4 m | 662.4 m | 662.4 m | 662.4 m | 662.4 m | SEC (XBRL)· 10 Feb 2026verified |
| Intangibles (excl. goodwill) | 46.5 m | 41.4 m | 38.0 m | 35.8 m | 34.4 m | 33.4 m | SEC (XBRL)· 10 Feb 2026verified |
| Total assets | 1.4 bn | 1.7 bn | 1.4 bn | 1.7 bn | 2.1 bn | 2.0 bn | SEC (XBRL)· 10 Feb 2026verified |
| Accounts payable | 26.6 m | 25.7 m | 33.1 m | 31.9 m | 32.5 m | 28.1 m | SEC (XBRL)· 10 Feb 2026verified |
| Short-term debt | — | 0 | 50.0 m | 0 | — | — | SEC (XBRL)· 13 Feb 2024verified |
| Current liabilities | 440.1 m | 557.2 m | 803.5 m | 925.1 m | 1.1 bn | 1.3 bn | SEC (XBRL)· 10 Feb 2026verified |
| Total liabilities | 584.9 m | 707.0 m | 966.1 m | 1.1 bn | 1.3 bn | 1.5 bn | SEC (XBRL)· 10 Feb 2026verified |
| Equity | 805.8 m † | 952.9 m † | 386.4 m † | 559.0 m † | 825.5 m † | 459.1 m † | SEC (XBRL)· 10 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 258.7 m | 263.3 m | 388.1 m | 433.4 m | 608.8 m | 713.2 m | SEC (XBRL)· 10 Feb 2026verified |
| Capex | 31.3 m | 28.3 m | 36.9 m | 36.6 m | 36.5 m | 31.4 m | SEC (XBRL)· 10 Feb 2026verified |
| Free cash flow | 227.3 m ≈ | 235.1 m ≈ | 351.2 m ≈ | 396.7 m ≈ | 572.3 m ≈ | 681.9 m ≈ | SEC (XBRL)· 10 Feb 2026derived |
| Investing cash flow | -31.2 m | -31.4 m | -38.7 m | -34.6 m | -28.3 m | -31.1 m | SEC (XBRL)· 10 Feb 2026verified |
| Financing cash flow | -82.3 m | -44.5 m | -775.8 m | -182.6 m | -154.0 m | -860.4 m | SEC (XBRL)· 10 Feb 2026verified |
| Share repurchases | 98.3 m | 62.1 m | 847.8 m | 144.0 m | 169.9 m | 917.4 m | SEC (XBRL)· 10 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 58.3% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 18.4 bn USD
Key indicators
Coverage and freshness
Score by group
58% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 877.05 – 1,219.65 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/E877.05 – 1,219.65 (Mid 1,176.36)3 companies used · median multiple 65.2x · quartiles 48.6x – 67.6xICLR, INCY, IQV
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 58.3% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 18.2% | 100 (vs peers) | 11% |
| FCF conversion · Quality | 128.9% | 100 (on a fixed band) | 11% |
| Revenue CAGR 3Y · Growth | 20.1% | 100 (on a fixed band) | 14% |
| EPS CAGR 3Y · Growth | 28.0% | 100 (on a fixed band) | 14% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 0.8x | 3 (on a fixed band) | 7% |
| P/E (TTM) · Valuation | 36.4x | 80 (vs peers) | 18% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 3.6% | 45 (on a fixed band) | 14% |
| Shareholder yield (distributions) · Returns | 1.6% | 23 (on a fixed band) | 11% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial3/100 · 1/3 factors with a value
- Growth100/100 · 2/2 factors with a value
- Quality100/100 · 2/3 factors with a value
- Returns· partial23/100 · 1/2 factors with a value
- Valuation65/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Medpace Holdings, Inc. (MEDP). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 2.5 bn USD in 2025; YoY growth 20.0%; net margin 18.2%; ROE 117.9%.
The estimated value range is 877.05–1,219.65 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 1,176.36 USD, the price of 656.77 USD leaves a potential of 79.1% (value / price − 1) and a margin of safety of 44.2% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 58.3% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 18.2%
- FCF conversion: 128.9%
- Revenue CAGR 3Y: 20.1%
- EPS CAGR 3Y: 28.0%
- P/E (TTM): 36.4x
- The price is below the estimated value range
What contradicts it
- Current ratio: 0.8x
- Shareholder yield (distributions): 1.6%
Not assessed (insufficient data or a ratio without meaning): ROIC, Net debt / EBITDA, Interest coverage, EV/EBITDA, Payout ratio (FCF).
Versus the vertical median
Services-Commercial Physical & Biological Research (SIC 8731) · same industry (4-digit SIC) · compared with 11 companies
The size band was not applied: too few companies would have remained; the vertical includes much smaller or larger companies.
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| IQVIqvia Holdings Inc. | 43.5 bn | 32.0 | 21.7% | 8.1% | +5.9% | +15% / +23% |
| INCYIncyte Corporation | 25.0 bn | 65.2 | 7.8% | 6.7% | +21.2% | +18% / +126% |
| MEDPMedpace Holdings, Inc. | 18.4 bn | 36.4 | 117.9% | 18.2% | +20.0% | +10% / +140% |
| CRLCharles River Laboratories International, Inc. | 15.6 bn | 385.5 | 1.2% | 1.0% | −0.9% | +83% / +66% |
| ICLRICON plc | 15.6 bn | 70.0 | 2.5% | 2.8% | +0.8% | +10% / −24% |
| ABSIAbsci Corp | 1.8 bn | — | -57.7% | -7,756.4% | −38.2% | +231% / +528% |
| OABIOmniab, Inc. | 755.6 m | — | -16.5% | -108.1% | −29.3% | +186% / +18% |
| NRCNRC Health | 574.5 m | 95.9 | 248.1% | 4.5% | −4.0% | +59% / −35% |
| ONMDOnemednet Corporation | 269.2 m | — | — | -584.2% | +111.4% | −75% / −89% |
| MXCTMaxCyte, Inc. | 143.5 m | — | -20.4% | -114.8% | −14.5% | −21% / −71% |
| BIAFbioAffinity Technologies, Inc. | 23.7 m | — | -1,860.2% | -257.3% | −34.2% | −87% / −100% |
| ISPCiSpecimen Inc. | 2.1 m | — | -968.5% | -2,449.0% | −79.2% | −95% / −100% |
1- and 3-year price returns: for MEDP from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 440.60 Total return -33% · Per year -33% | 775.40 Total return 18% · Per year 18% | 1,163.09 Total return 77% · Per year 77% |
| 3 years | 522.63 Total return -20% · Per year -7% | 1,025.46 Total return 56% · Per year 16% | 1,674.86 Total return 155% · Per year 37% |
| 5 years | 619.92 Total return -6% · Per year -1% | 1,356.17 Total return 106% · Per year 16% | 2,411.79 Total return 267% · Per year 30% |
- Exit P/E± 256.37
- Net margin± 179.46
- Annual revenue growth± 133.84
- Annual dilution± 15.08
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 26 Oct 2026 · Model: claude-sonnet-5-5.
Possibly outdated: the newest document it read is from 21 Oct 2026; since then the company filed 10-Q (22 Oct 2026).
In brief
Medpace is a contract research organization (CRO) that runs full-service clinical trials for small and mid-sized biotech and pharma companies. In Q3 2026 net new awards exceeded revenue, management narrowed its revenue guidance range and approved a new buyback program 12.
SWOT
Strengths
Weaknesses
- Concentration in small and mid-sized biotech clients, which are sensitive to funding.
- Backlog can shrink through cancellations, affecting future revenue.
- The stock is often valued richly versus the sector, leaving little room for disappointment.
Opportunities
- A recovery in biotech funding.
- Expansion into new therapeutic areas and big pharma clients.
- Automation and AI in trial planning and monitoring.
Threats
- Another funding drought for biotech.
- Waves of cancelled or delayed trials.
- Price pressure from larger CROs.
- New drug-pricing rules that would cut R&D budgets.
Risks
- Trial cancellationshigh
Cancellations reduce backlog and future revenue; a new wave could appear if client funding weakens 4.
- Dependence on biotech fundinghigh
Small clients rely on capital markets to pay for trials.
- Backlog conversionmedium
The 23.8% conversion rate shows how fast awards turn into revenue; a slowdown would delay growth 1.
- Concentration in a few therapeutic areasmedium
Q4 2025 cancellations were slightly skewed toward the metabolic area 4; concentrated exposure amplifies such episodes.
- Capital allocationlow
The 1.0 bn USD buyback is funded from cash; if the cycle turned, flexibility would shrink 1.
Investment thesis
What would need to be true (bull case)
What would break the thesis
- Awards fall below revenue for several quarters in a row.
- Cancellations return to or exceed the Q4 2025 level.
- Biotech funding tightens.
- Rising staff costs compress margin.
What to watch
- Q4 2026 results and 2027 guidance (revenue, EBITDA)February 2027
- Net new awards and book-to-billQ4 2026
- Cancellation levelQ4 2026
- Pace of repurchases under the new programQ4 2026 - 2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 26 Oct 2026 · Model: claude-sonnet-5-5.
Possibly outdated: the newest document it read is from 21 Oct 2026; since then the company filed 10-Q (22 Oct 2026).
The business
Medpace provides full-service clinical development: trial design, site management, monitoring, biostatistics, central labs and reporting. Clients are mainly small and mid-sized biotechs, often without an in-house clinical department.
Revenue is recognized over the course of trials, from backlog (signed but unexecuted awards). Backlog of 3,167.2 million USD at September 30, 2026 gives medium-term visibility 1.
Segments
Full-service clinical development
Nearly all activity: early- and late-phase trials, with a focus on oncology, metabolic disease, cardiology and other therapeutic areas.
Central laboratories
In-house labs that process trial samples and support quality control and execution speed.
Market context
The CRO market depends on pharma R&D spending and, especially for Medpace, on biotech funding: when capital is easy to raise, new trials appear; when it tightens, awards are delayed or cancelled.
The indicators to follow are net new awards, the book-to-bill ratio, backlog and cancellations. In Q4 2025 backlog cancellations reached their highest level in over a year and lowered the ratio that quarter; management said it saw no reason for that level to continue 4.
Trends
- Awards above revenuetailwind
Net new awards were 873.4 million USD in Q3 2026 against revenue of 716.0 million USD, a ratio of about 1.22 (own calculation) 1.
- Growing backlogtailwind
Backlog rose 5.6% to 3,167.2 million USD, and the conversion rate was 23.8% 1.
- Biotech fundingmixed
A more open capital market for biotechs supports new trials; a closed market would slow awards with a lag of a few quarters.
- Cancellationsheadwind
Cancellations in Q4 2025 were the highest in over a year, spread across projects and slightly skewed toward the metabolic area, according to management; they remain the main risk indicator for backlog 4.
- Narrowed guidancemixed
2026 revenue guidance is now 2.835 to 2.855 bn USD 1, narrowed from 2.805 to 2.885 bn USD in July with the same midpoint 2, and above the 2.755 to 2.855 bn USD given in February 3.
Competitive position
Medpace competes with large, broad-portfolio CROs and with smaller firms. It positions itself on full-service work for small and mid-sized clients, with a centralized execution model and in-house labs.
EBITDA margin rose to 24.0% in Q3 2026 from 22.5% a year earlier, a sign of cost discipline 1.
- IQVIAIQV
Largest CRO, with added data and technology services.
- ICONICLR
Large global CRO with big pharma and biotech clients.
- FortreaFTRE
CRO spun off from Labcorp, in the middle of a reorganization.
- Charles River LaboratoriesCRL
Preclinical and research services, partly overlapping.
- Parexel and Syneos Health
Large unlisted CROs.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Medpace Stock Hovers Near Entry, Offers Second Chance After July SpikeYahoo Finance — News · 26 Aug 2026 · EN
- What Investors Should Know About Medpace CEO Troendle Selling $10 Million in StockYahoo Finance — News · 26 Aug 2026 · EN
The latest news item in our archive is from 26 Aug 2026; the newest SEC filing is from 22 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Quarterly report22 Oct 2026
- Current report21 Oct 2026Results of operations · Other events · Financial statements and exhibits
- Quarterly report23 Jul 2026
- Current report22 Jul 2026Results of operations · Financial statements and exhibits
- Current report04 Jun 2026Departure or appointment of officers
- Current report19 May 2026Amendments to articles or bylaws · Shareholder vote · Financial statements and exhibits
- Quarterly report23 Apr 2026
- Current report22 Apr 2026Results of operations · Departure or appointment of officers · Financial statements and exhibits
- Proxy statement01 Apr 2026
- Annual report10 Feb 2026
Sources
- [1] Form 8-K, comunicatul de rezultate Q3 2026 · SEC / Medpace · 21 Oct 2026
- [2] Form 8-K, comunicatul de rezultate Q2 2026 · SEC / Medpace · 22 Jul 2026
- [3] Rezultate trimestrul IV și anul 2025, ghidaj 2026 (Form 8-K, anexa 99.1) · SEC / Medpace · 09 Feb 2026
- [4] Medpace Q4 2025 Earnings Call Transcript · MarketBeat · 10 Feb 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.